Asset profile
Forvisirvat
Small molecule
Evidence outlook · lead readout
NCT04479852 · Major Depressive Disorder
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT04479852: The study randomized 319 participants to SP-624 or placebo and used quadruple masking, with 132 SP-624 and 125 placebo participants included in the primary analysis. Its clinical primary endpoint, change in MADRS score at Week 4, was not statistically significant (p=0.133), so the results provide well-controlled but inconclusive evidence of benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.